Central Nervous System Involvement in Epstein–Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation

Balaguer‐Roselló, Aitana; Piñana, José Luís; Bataller, Luís; Montoro, Juan; Romero, Samuel; Navarro, Irene; Lorenzo, Ignacio; Andreu, Rafael; Guerreiro, Manuel; Aguilar-Gallardo, Cristóbal; Górriz, David; Domínguez, Lara; Puerta, Rosalía de la; Gómez, Inés; Solves, Pilar; Jarque, Isidro; Sanz, Miguel Á.; Sanz, Guillermo; Sanz, Jaime

doi:10.1016/j.jtct.2020.12.019

Cited by 4 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a review of 84 cases, Evens et al reports the average time from transplant to diagnosis to be approximately 54 months. Most authors note the latency period following HSCT to be the shortest [16] , [17] , [18] .…”

Section: Discussionmentioning

confidence: 99%

“…6 A PRISMA flowchart of our screening and review process. [2 , 3 , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , 38 , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [51] , [52] , [53] , [54] , 57 , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , …”

Section: Methodsunclassified

See 1 more Smart Citation

Primary central nervous system post-transplantation lymphoproliferative disorder: A case report and systematic review of imaging findings

Hoyt,

Hughes,

Liu

et al. 2024

Radiology Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Methodsunclassified

Primary central nervous system post-transplantation lymphoproliferative disorder: A case report and systematic review of imaging findings

Hoyt,

Hughes,

Liu

et al. 2024

Radiology Case Reports

View full text Add to dashboard Cite

“…There were fewer than 50 PCNS-PTLD cases post-HSCT reported in literature, with neuroimaging data available for only 28 patients [4,[7][8][9][10][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38], as summarized in our literature review. Patients with PCNS-PTLD commonly presented with symptoms of elevated intracranial pressure such as headache, nausea, vomiting, and decreased consciousness (Table S1) [39,40].…”

Section: Discussionmentioning

confidence: 99%

Neuroimaging features of primary central nervous system post-transplantation lymphoproliferative disorder following hematopoietic stem cell transplant in patients with β-thalassemia: a case series and review of literature

Yang,

Deng,

et al. 2024

Insights Imaging

View full text Add to dashboard Cite

Purpose Primary central nervous system post-transplantation lymphoproliferative disorder (PCNS-PTLD) is a rare but serious complication of hematopoietic stem cell transplantation (HSCT) in patients with severe β-thalassemia. This study aimed to assess the clinical presentation, pathological characteristics, neuroimaging findings, and treatment strategies in patients with β-thalassemia who developed PCNS-PTLD and to compare a case series from our transplant center to reported cases from literature. Methods We retrospectively reviewed our hospital database and identified four cases of pathologically confirmed PCNS-PTLD without a history of systemic PTLD in patients with severe β-thalassemia after HSCT. We also performed a relevant literature review on PCNS-PTLD. Results The median time from transplantation to diagnosis of PCNS-PTLD was 5.5 months. Intracerebral lesions were usually multiple involving both supratentorial and infratentorial regions with homogeneous or rim enhancement. All patients had pathologically confirmed PCNS-PTLD with three patients having diffuse large B-cell lymphoma and the fourth patient having plasmacytic hyperplasia. There was low response to treatment with a median survival of 83 days. Conclusion PCNS-PTLD should be considered in the differential diagnosis of patients with β-thalassemia who had an intracranial lesion on neuroimaging after HSCT. Critical relevance statement This case series with a comprehensive review of neuroimaging and clinical characteristics of children with primary central nervous system post-transplantation lymphoproliferative disorder should advance our understanding and improve management of this rare yet severe complication following transplant for β-thalassemia. Key points • We assessed clinical presentation, treatment strategies, and neuroimaging characteristics of PCNS-PTLD in patients with β-thalassemia after transplantation. • Patients with β-thalassemia may have post-transplantation lymphoproliferative disorder presenting as brain lesions on neuroimaging. • Neuroimaging findings of the brain lesions are helpful for prompt diagnosis and proper management. Graphical Abstract

show abstract

“…EBV also plays a vital role in several lymphoproliferative disorders (LPDs) occurring in immunocompromised and immunocompetent hosts. [5][6][7] Given the varied and nonspecific clinical manifestations, EBV antibodies and polymerase chain reaction (PCR) analysis in blood or CSF are often used for confirmation. 8 The high soft-tissue contrast resolution of MR imaging is an essential tool during initial work-up and follow-up.…”

mentioning

confidence: 99%

Unpacking the CNS Manifestations of Epstein-Barr Virus: An Imaging Perspective

Soni

Ora

Singh

et al. 2023

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

Epstein-Barr virus is a ubiquitous herpesvirus that may cause both infective (encephalitis, meningitis, and so forth) and postinfection inflammatory (such as Guillain-Barré syndrome, acute disseminated encephalomyelitis) manifestations in the CNS. Diagnosis of Epstein-Barr virus-related CNS pathologies is often complicated due to a nonspecific clinical presentation and overlap with other infectious and noninfectious causes, both clinically and on imaging. The Epstein-Barr virus is also implicated in several lymphoproliferative disorders in both immunocompromised and immunocompetent hosts. MR imaging is preferred for evaluating the extent of involvement and monitoring therapy response, given its high sensitivity and specificity, though imaging findings may be nonspecific. Herein, we review the imaging spectrum of Epstein-Barr virus-associated CNS disorders.ABBREVIATIONS: ADEM ¼ acute disseminated encephalomyelitis; ATM ¼ acute transverse myelitis; EBV ¼ Epstein-Barr virus; EBNA ¼ Epstein-Barr nuclear antigen; Ig ¼ immunoglobulin; LG ¼ lymphomatoid granulomatosis; LPD ¼ lymphoproliferative disorder; MOG ¼ myelin oligodendrocyte glycoprotein; PCNSL ¼ primary CNS lymphoma; PCR ¼ polymerase chain reaction; PTLD ¼ posttransplant lymphoproliferative disorder; SMT ¼ smooth-muscle tumor

show abstract

Central Nervous System Involvement in Epstein–Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation

Cited by 4 publications

References 40 publications

Primary central nervous system post-transplantation lymphoproliferative disorder: A case report and systematic review of imaging findings

Primary central nervous system post-transplantation lymphoproliferative disorder: A case report and systematic review of imaging findings

Neuroimaging features of primary central nervous system post-transplantation lymphoproliferative disorder following hematopoietic stem cell transplant in patients with β-thalassemia: a case series and review of literature

Unpacking the CNS Manifestations of Epstein-Barr Virus: An Imaging Perspective

Contact Info

Product

Resources

About